BLX-7006

BLX-7006 is an investigational oral small molecule drug developed by Biolexis Therapeutics for the treatment of obesity and type 2 diabetes. It acts as a first-in-class allosteric agonist of the glucagon-like peptide 1 receptor (GLP-1 receptor), promoting appetite suppression and glucose regulation. Unlike existing GLP-1 agonists that are typically peptide-based and require injection, BLX-7006 is orally administered and features a novel chemotype with a unique binding mode distinct from other small-molecule GLP-1 therapies. Preclinical studies in diet-induced obese mice demonstrated significant weight loss efficacy—comparable to semaglutide—with an average reduction of up to 15% over 28 days at standard doses and up to 29% at higher doses. The drug has also shown promising results in animal models of type 2 diabetes, improving insulin sensitivity and metabolic parameters. Early toxicology data suggest it is well tolerated with no observed organ toxicities[1][2][4][5][7].